Lexeo Stock Jumps as FDA Opens Door to NSVT Pivotal Endpoint for LX2020

Lexeo Stock Jumps as FDA Opens Door to NSVT Pivotal Endpoint for LX2020

Seven people. That is the entire high-dose group behind Lexeo Therapeutics’ climb of roughly 25% to 28% on Monday. Their bursts of abnormal heart rhythm fell 80% on average, and the FDA now says that measure could anchor a pivotal trial. Medicenna and Rapid Micro Biosystems also had news on November 16, one with a brain cancer survival readout and the other with a buyout at 75 cents a share.

Lexeo Rises as FDA Opens Door to NSVT Endpoint for LX2020

Lexeo Therapeutics (Nasdaq: LXEO) reported new interim data from its HEROIC-PKP2 trial of LX2020 on November 16, alongside third-quarter results. LX2020 is an investigational gene therapy for PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), an inherited heart muscle disease that causes dangerous rhythm problems.

Among the seven patients on the higher dose, non-sustained ventricular tachycardia (NSVT), short runs of fast heartbeat starting in the heart’s lower chambers, fell 80% on average from baseline as of an October 15 data cutoff. Six of the seven improved. Premature beats dropped 44%, a second rhythm measure moving the same direction, and five of seven patients reported feeling better at their latest visit.

Rare-disease gene therapies live or die on finding an endpoint a small trial can actually hit. The FDA told Lexeo it is open to guideline-defined NSVT as the primary surrogate endpoint in a pivotal study aimed at accelerated approval. Open is not agreed. Lexeo expects to lock the trial design and statistical plan in the first half of 2027 and start the study in the second half. Shares jumped about 25% before the open and stood 28.22% higher by mid-morning.

The trial is single-arm and open-label, so there is no placebo group to measure against. One patient had a Grade 3 serious adverse event of ventricular tachycardia three months after dosing, and liver function test elevations at the high dose were managed under the protocol. LX2020’s RMAT, Orphan Drug and Fast Track designations are not approvals. Lexeo had $219.1 million in cash and investments at September 30, enough to last into 2028 by its own estimate, after a $38.3 million third-quarter net loss.

Medicenna Reports 13.7-Month Glioblastoma Survival With Bizaxofusp

Medicenna Therapeutics (TSX: MDNA; OTCQB: MDNAF) released survival data for its investigational drug bizaxofusp on November 16, after an oral presentation at the Society for Neuro-Oncology meeting in Philadelphia. Nineteen patients with unresectable, recurrent IDH-wildtype glioblastoma who received at least 180 µg lived a median 13.7 months. Matched patients from an outside comparison group lived 6.2 months (hazard ratio 0.499, p=0.013), more than double on paper.

The drug is given once, through convection-enhanced delivery, an infusion pushed directly into brain tissue through surgically placed catheters.

That comparison group was never randomized. It is an external control arm, built from past patient records at UCSF and St. Michael’s Hospital and statistically weighted on 10 prognostic factors, and Medicenna’s own release warns it is open to residual confounding. Across all 44 per-protocol patients, median survival was 12.5 months versus 7.2. Bizaxofusp has FDA Fast Track and Orphan Drug designations, which are not approvals.

At an End-of-Phase 2 meeting, the FDA agreed a hybrid Phase 3 was feasible: about 200 randomized patients, roughly 150 on bizaxofusp and 50 on standard care, topped up with an external control equal to about 100 more, with overall survival as the primary endpoint.

Paying for it is the open question. Medicenna had C$5.7 million in cash at June 30, and its June runway guidance through the first quarter of calendar 2027 assumed a separate structured financing with Sorbie closes as planned. Shareholders backed a potential share consolidation in early October. Liquidity is thin at a market value of roughly C$30 million.

Merck KGaA Agrees to Buy Rapid Micro Biosystems for $0.75 a Share

Merck KGaA, Darmstadt, Germany agreed to acquire Rapid Micro Biosystems (Nasdaq: RPID) for $0.75 per share in cash on November 16. Rapid Micro makes the Growth Direct system, which automates microbial quality-control testing in drug manufacturing, and Merck’s life science business already distributes it under a global agreement announced in February 2025.

The price values the company at roughly $39 million, about 15% above the prior close, according to InsideArbitrage. Neither company’s release states a premium.

Rapid Micro’s balance sheet helps explain the modest markup. Third-quarter revenue grew 21.6% to $9.5 million and gross margin hit a record 25.2%, but the company lost $11.3 million in the quarter and ended September with about $7 million in cash and short-term investments. Full-year guidance is withdrawn, and the quarterly 10-Q will arrive late under an SEC filing extension.

The deal runs as a tender offer and needs holders of a majority of voting shares, counting shares from pre-funded warrants, to tender. Closing is targeted for December. For holders weighing the price, the board’s formal recommendation arrives in a Schedule 14D-9 once the offer opens.

LXEO, MDNA, RPID: Forward-Looking FAQ

Has the FDA signed off on NSVT as the primary endpoint for a pivotal LX2020 trial?

Not yet. The FDA said only that it is open to NSVT as a primary surrogate endpoint. Lexeo expects to finalize the design, statistical plan and confirmatory evidence strategy in the first half of 2027 and start the study in the second half.

Can Medicenna fund a 200-patient hybrid Phase 3 of bizaxofusp with the cash it has disclosed?

Nothing disclosed so far covers a trial that size. Its latest runway guidance reaches the first quarter of calendar 2027 and depends on the Sorbie financing closing, so a Phase 3 would likely need new capital or a partner.

What has to happen before Rapid Micro shareholders receive Merck KGaA’s $0.75 per share?

The tender offer has to open with a Schedule TO filing, and holders of a majority of voting shares, including shares from pre-funded warrant exercises, must tender. Both companies are targeting a December 2026 close, subject to customary conditions.

Sources

Editorial Disclosure

Sources: SEC Form 8-K filings, company press releases via GlobeNewswire, company IR pages, named financial press. Securities discussed: Lexeo Therapeutics, Inc. (Nasdaq: LXEO); Medicenna Therapeutics Corp. (TSX: MDNA; OTCQB: MDNAF); Rapid Micro Biosystems, Inc. (Nasdaq: RPID). aktiego.com has received no compensation from any company, IR firm, or third party mentioned. No aktiego.com staff or principal holds a position in LXEO, MDNA/MDNAF, or RPID. Press release dates verified: Lexeo, Medicenna, and Rapid Micro Biosystems, November 16, 2026. Lexeo: LX2020 is investigational and not FDA approved; HEROIC-PKP2 is single-arm and open-label; efficacy figures cover seven high-dose patients; one Grade 3 serious adverse event of ventricular tachycardia reported; FDA openness to an NSVT surrogate endpoint is not an agreed pivotal protocol; RMAT, Orphan Drug, and Fast Track designations are not approvals. Medicenna: bizaxofusp is investigational and not approved; survival comparison uses a non-randomized external control arm and the headline result rests on 19 patients; cash of C$5.7 million at June 30, 2026; runway guidance assumes completion of a pending structured financing; shareholders backed a potential share consolidation; market cap approximately C$30 million, thinly traded and highly volatile. Rapid Micro Biosystems: acquisition is pending and not closed; closing requires tender of a majority of voting shares and customary conditions; premium figure is from secondary reporting, not company disclosure; approximately $7 million in cash and short-term investments at September 30, 2026 against a $11.3 million quarterly net loss; full-year guidance withdrawn; quarterly 10-Q filing delayed under Rule 12b-25. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.

AktieGo

More Market Insights
on YouTube

Watch our latest market briefings, CEO interviews and stock deep dives covering the companies and sectors we follow.

Nvidia's $500 Billion AI Financing Bet
Nvidia’s $500 BILLION AI Financing Bet: Brilliant Move or Hidden Risk?
The Drone Revolution: Why Warfare Has Changed Forever
The Drone Revolution: Why Warfare Has Changed Forever
The AI CyberSecurity Arms Race Has Begun
The AI CyberSecurity Arms Race Has Begun
Market Briefings
3× per week
Stock Deep Dives
In-depth analysis
CEO Interviews
Exclusive insights
Emerging Sectors
Mining · Tech · Energy · Biotech
The AktieGo Brief

The market moves fast.
Our briefing keeps up.

Curated updates on stock picks, company spotlights, and in-depth market analysis across mining, biotech, energy, crypto, and tech — delivered straight to your inbox. Join thousands of investors who start their morning with the AktieGo Brief.



Name

BRIEF